Relationship between tumor enhancement, edema, IDH1 mutational status, MGMT promoter methylation, and survival in glioblastoma
JA Carrillo, A Lai, PL Nghiemphu… - American Journal …, 2012 - Am Soc Neuroradiology
BACKGROUND AND PURPOSE: Both IDH1 mutation and MGMT promoter methylation are
associated with longer survival. We investigated the ability of imaging correlates to serve as …
associated with longer survival. We investigated the ability of imaging correlates to serve as …
Prognostic or predictive value of MGMT promoter methylation in gliomas depends on IDH1 mutation
Objective: To explore whether the isocitrate dehydrogenase 1 (IDH1) or 1p/19q status
determines the prognostic vs predictive role of O6-methylguanine-DNA methyltransferase …
determines the prognostic vs predictive role of O6-methylguanine-DNA methyltransferase …
The combination of IDH1 mutations and MGMT methylation status predicts survival in glioblastoma better than either IDH1 or MGMT alone
RJ Molenaar, D Verbaan, S Lamba, C Zanon… - Neuro …, 2014 - academic.oup.com
Background Genetic and epigenetic profiling of glioblastomas has provided a
comprehensive list of altered cancer genes of which only O6-methylguanine …
comprehensive list of altered cancer genes of which only O6-methylguanine …
The survival outcomes of molecular glioblastoma IDH-wildtype: a multicenter study
Purpose Histological diagnosis of glioblastoma (GBM) was determined by the presence of
necrosis or microvascular proliferation (histGBM). The 2021 WHO classification now …
necrosis or microvascular proliferation (histGBM). The 2021 WHO classification now …
[HTML][HTML] IDH mutation and MGMT promoter methylation in glioblastoma: results of a prospective registry
P Yang, W Zhang, Y Wang, X Peng, B Chen, X Qiu… - Oncotarget, 2015 - ncbi.nlm.nih.gov
Background The relative contribution of isocitrate dehydrogenase mutations (mIDH) and O6-
methylguanine-DNA methyltransferase promoter methylation (methMGMT) as biomarkers in …
methylguanine-DNA methyltransferase promoter methylation (methMGMT) as biomarkers in …
[HTML][HTML] Molecular biomarkers in glioblastoma: A systematic review and meta-analysis
Background: Glioblastoma (GBM) is a highly aggressive cancer with poor prognosis that
needs better treatment modalities. Moreover, there is a lack of reliable biomarkers to predict …
needs better treatment modalities. Moreover, there is a lack of reliable biomarkers to predict …
[HTML][HTML] Predictive MGMT status in a homogeneous cohort of IDH wildtype glioblastoma patients
J Radke, A Koch, F Pritsch, E Schumann… - Acta neuropathologica …, 2019 - Springer
Abstract Methylation of the O (6)-Methylguanine-DNA methyltransferase (MGMT) promoter is
predictive for treatment response in glioblastoma patients. However, precise predictive cutoff …
predictive for treatment response in glioblastoma patients. However, precise predictive cutoff …
The prognostic value of IDH mutations and MGMT promoter status in secondary high-grade gliomas
TA Juratli, M Kirsch, K Geiger, B Klink, E Leipnitz… - Journal of neuro …, 2012 - Springer
Reports about the prognostic value of IDH mutations and the promoter region of the O6-
Methyl-guanyl-methyl-transferase gene in secondary high-grade gliomas (sHGG) are few in …
Methyl-guanyl-methyl-transferase gene in secondary high-grade gliomas (sHGG) are few in …
Surgery for glioblastoma in light of molecular markers: impact of resection and MGMT promoter methylation in newly diagnosed IDH-1 wild-type glioblastomas
F Gessler, JD Bernstock, A Braczynski, S Lescher… - …, 2019 - journals.lww.com
BACKGROUND Previous studies addressing the influence of surgery on the outcome of
patients with glioblastomas (GBM) have not addressed molecular markers. The value of …
patients with glioblastomas (GBM) have not addressed molecular markers. The value of …
[HTML][HTML] XGBoost improves classification of MGMT promoter methylation status in IDH1 wildtype glioblastoma
Approximately 96% of patients with glioblastomas (GBM) have IDH1 wildtype GBMs,
characterized by extremely poor prognosis, partly due to resistance to standard …
characterized by extremely poor prognosis, partly due to resistance to standard …
